<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAW</journal-id>
<journal-id journal-id-type="hwp">sptaw</journal-id>
<journal-title>Therapeutic Advances in Drug Safety</journal-title>
<issn pub-type="ppub">2042-0986</issn>
<issn pub-type="epub">2042-0994</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2042098612444867</article-id>
<article-id pub-id-type="publisher-id">10.1177_2042098612444867</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>High-risk prescribing and monitoring in primary care: how common is it, and how can it be improved?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Dreischulte</surname><given-names>Tobias</given-names></name>
<aff id="aff1-2042098612444867">University of Dundee - Population Health Sciences, Kirsty Semple Way, Dundee, UK</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Guthrie</surname><given-names>Bruce</given-names></name>
<aff id="aff2-2042098612444867">University of Dundee - Population Health Sciences, Kirsty Semple Way, Dundee, UK</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2042098612444867"><email>t.dreischulte@dundee.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>4</issue>
<fpage>175</fpage>
<lpage>184</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The safety of medication use in primary care is an area of increasing concern for health systems internationally. Systematic reviews estimate that 3–4% of all unplanned hospital admissions are due to preventable drug-related morbidity, the majority of which have been attributed to shortcomings in the prescribing and monitoring stages of the medication use process. We define high-risk prescribing as medication prescription by professionals, for which there is evidence of significant risk of harm to patients, and which should therefore either be avoided or (if avoidance is not possible) closely monitored and regularly reviewed for continued appropriateness. Although prevalence estimates vary depending on the instrument used, cross-sectional studies conducted in primary care equivocally show that it is common and there is evidence that it can be reduced. Quality improvement strategies, such as clinical decision support, performance feedback and pharmacist-led interventions have been shown to be effective in reducing prescribing outcomes but evidence of improved patient outcomes remains limited. The increasing implementation of electronic medical records in primary care offer new opportunities to combine different strategies to improve medication safety in primary care and to integrate services provided by different stakeholders. In this review article, we describe the spectrum of high-risk medication use in primary care, review approaches to its measurement and summarize research into its prevalence. Based on previously developed interventions to change professional practice, we propose a systematic approach to improve the safety of medication use in primary care and highlight areas for future research.</p>
</abstract>
<kwd-group>
<kwd>adverse drug event</kwd>
<kwd>clinical decision support system</kwd>
<kwd>medication error</kwd>
<kwd>medication safety</kwd>
<kwd>performance feedback</kwd>
<kwd>primary healthcare</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2042098612444867">
<title>Background</title>
<p>Although licensing systems across the world are designed to ensure that medicinal products entering the market have a favourable risk–benefit balance, drugs frequently cause harm across all healthcare sectors, much of which is preventable. In primary care, the size of the problem is illustrated by systematic reviews which estimate that 3–4% of all unplanned hospital admissions are due to preventable drug-related morbidity [<xref ref-type="bibr" rid="bibr29-2042098612444867">Howard <italic>et al</italic>. 2006</xref>]. In addition, hospital admissions are only the tip of the iceberg of drug-related harm and inconvenience to patients since many preventable adverse drug events (pADEs) are managed in primary care. One systematic review estimates that almost 7 pADEs occur per 100 outpatients annually, of which only a small proportion require hospital admission [<xref ref-type="bibr" rid="bibr55-2042098612444867">Thomsen <italic>et al</italic>. 2007</xref>].</p>
<p>The medication use process in primary care comprises the consecutive stages of prescribing, dispensing, drug administration and medication monitoring, which are shared across a multidisciplinary team of professionals, informal carers and patients [<xref ref-type="bibr" rid="bibr25-2042098612444867">Hepler and Segal, 2003</xref>]. While systematic reviews attribute the vast majority of pADEs in primary care in approximately equal parts to shortcomings in prescribing, patient nonadherence and monitoring [<xref ref-type="bibr" rid="bibr29-2042098612444867">Howard <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr55-2042098612444867">Thomsen <italic>et al</italic>. 2007</xref>], this review article focuses on prescribing and monitoring since these are more directly under professional control. We describe the spectrum of high-risk medication use in primary care, review approaches to its measurement and summarise research into its prevalence. Based on previously developed interventions to change professional practice, we propose a systematic approach to improve the safety of medication use in primary care and highlight areas for future research.</p>
</sec>
<sec id="section2-2042098612444867">
<title>Definition of high-risk prescribing</title>
<p>A pADE has been defined by the United States Institute of Medicine as ‘any preventable injury due to medication’ [<xref ref-type="bibr" rid="bibr6-2042098612444867">Bates <italic>et al</italic>. 1995</xref>]. The causes of pADEs are generally referred to as medication errors, which encompass ‘failures in the treatment process that lead to, or have the potential to lead to, harm to the patient’, including deficiencies in prescribing and monitoring [<xref ref-type="bibr" rid="bibr2-2042098612444867">Aronson, 2009</xref>].</p>
<p>Prescribing medicines is an inherently risky and often complex task. Cribb and Barber define appropriate prescribing as ‘a balance between the right technical properties, what patients want and the greater good’ highlighting the potential for conflicts between the different rationales for prescribing [<xref ref-type="bibr" rid="bibr9-2042098612444867">Cribb and Barber, 1997</xref>]. Labelling prescribing ‘inappropriate’ or ‘erroneous’ in cases where medication use violates a predefined rule can therefore be simplistic [<xref ref-type="bibr" rid="bibr25-2042098612444867">Hepler and Segal, 2003</xref>]. For example, prescription of a nonsteroidal anti-inflammatory drug (NSAID) to a patient taking warfarin is clearly high risk, but will occasionally be appropriate. For a prescriber faced with a patient with active rheumatoid arthritis who has recently been anticoagulated for thromboembolic disease, coprescription may be the least bad choice. We define high-risk prescribing as medication prescription by professionals, for which there is evidence of significant risk of harm to patients, and which should therefore either be avoided or (if avoidance is not possible) closely monitored and regularly reviewed for continued appropriateness.</p>
</sec>
<sec id="section3-2042098612444867">
<title>The spectrum of high-risk prescribing in primary care</title>
<p>In a systematic review of studies investigating the drugs most frequently implicated in preventable hospital admissions, four drug classes accounted for approximately 50% of preventable drug-related hospitalizations: antiplatelet drugs, NSAIDs, diuretics and anticoagulants. A further 21% of preventable admissions were attributed to other cardiovascular agents (beta blockers, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers, cardiac glycosides), opioid analgesics and antidiabetic agents [<xref ref-type="bibr" rid="bibr29-2042098612444867">Howard <italic>et al</italic>. 2006</xref>]. The bulk of preventable harm in terms of hospital admissions is therefore not due to drugs that should generally be avoided because the risk of harm usually exceeds expected benefits, but rather to therapeutic agents that are commonly used in primary care and have strong indications (the obvious exception being NSAIDs used as simple analgesics).</p>
<p><xref ref-type="table" rid="table1-2042098612444867">Table 1</xref> summarizes common patterns of high-risk prescribing that have been implicated in preventable hospital admissions [<xref ref-type="bibr" rid="bibr28-2042098612444867">Howard <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr55-2042098612444867">Thomsen <italic>et al</italic>. 2007</xref>], demonstrating that preventable harm is often the consequence of not recognizing or taking insufficient account of patients’ needs at a time of particular vulnerability. The following types of preventable hospital admission can generally be distinguished (although they may overlap in individual patients): (1) continuing drugs that are not indicated or no longer indicated, (2) not using drugs that are indicated to prevent adverse drug reactions, (3) using drugs or drug doses that interact with existing medical conditions, (4) using drugs or drug doses that interact with existing drug therapy and (5) inconsistent monitoring.</p>
<table-wrap id="table1-2042098612444867" position="float">
<label>Table 1.</label>
<caption>
<p>Reported scenarios of high-risk use of drugs most frequently implicated in preventable drug related hospital admissions [<xref ref-type="bibr" rid="bibr28-2042098612444867">Howard <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr55-2042098612444867">Thomsen <italic>et al</italic>. 2007</xref>].</p>
</caption>
<graphic alternate-form-of="table1-2042098612444867" xlink:href="10.1177_2042098612444867-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Drug class</th>
<th align="left">High-risk prescribing</th>
<th align="left">Preventable adverse drug event</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAID/ antiplatelets/ oral anticoagulants</td>
<td>Prescription in patient with GI risk factors (without GI protection)</td>
<td>GI toxicity, haemorrhage, anaemia</td>
</tr>
<tr>
<td/>
<td>Coprescription of NSAIDs and antithrombotics (without GI protection)</td>
<td/>
</tr>
<tr>
<td>NSAID</td>
<td>Overdosing due to prescription of two full-dose NSAIDs</td>
<td>Acute renal failure</td>
</tr>
<tr>
<td>Opioid analgesic</td>
<td>Prescription without laxative</td>
<td>Constipation</td>
</tr>
<tr>
<td>ACE inhibitor/ ARB</td>
<td>Prescription in patient with aortic stenosis</td>
<td>Pulmonary oedema</td>
</tr>
<tr>
<td>Diuretics</td>
<td>Coprescription of thiazide and loop diuretic (without valid indication)</td>
<td>Hyponatraemia, dehydration, hypotension, renal failure</td>
</tr>
<tr>
<td/>
<td>Overdosing due to lack of monitoring of fluid balance, renal function, electrolytes, etc.</td>
<td/>
</tr>
<tr>
<td>ACE inhibitor/ARB/ diuretics</td>
<td>Coprescription of potassium sparing diuretic (without valid indication)</td>
<td>Hyperkalaemia</td>
</tr>
<tr>
<td>Beta blocker/ Calcium antagonists</td>
<td>Coprescription of verapamil (without valid indication)</td>
<td>Congestive cardiac failure</td>
</tr>
<tr>
<td>Oral anticoagulants</td>
<td>Overdosing due to lack of INR monitoring in patient known to be hard to control or following introduction of an antibiotic</td>
<td>Haemorrhage/anaemia</td>
</tr>
<tr>
<td>Antidiabetics</td>
<td>Overdosing due to lack of GFR monitoring in patient taking sulphonylurea</td>
<td>Hypoglycaemia</td>
</tr>
<tr>
<td/>
<td>Overdosing due to lack of blood glucose monitoring following introduction of prednisolone</td>
<td>Hypoglycaemia</td>
</tr>
<tr>
<td/>
<td>Overdosing due to no dose reduction when hypoglycaemia noted</td>
<td>Hypoglycaemia</td>
</tr>
<tr>
<td>Digoxin</td>
<td>Overdosing due to lack of GFR/digoxin level monitoring</td>
<td>Digoxin toxicity</td>
</tr>
<tr>
<td>Beta blockers</td>
<td>Overdosing due to treatment initiation at full dose in patient with congestive heart failure</td>
<td>Congestive cardiac failure</td>
</tr>
<tr>
<td/>
<td>Sudden cessation without down-titration of dose</td>
<td>Tachycardia</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2042098612444867">
<p>ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; GFR, glomerular filtration rate; GI, gastrointestinal; NSAID, nonsteroidal anti-inflammatory drug.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-2042098612444867">
<title>Measurement and prevalence</title>
<p>The safety of medication use can generally be assessed using ‘implicit’ or ‘explicit’ approaches. ‘Implicit’ methods allow the assessor maximum flexibility to account for the clinical context within which prescribing and monitoring decisions take place, whereas ‘explicit’ methods assess medication use against prespecified rules. At the individual patient level, explicit ‘assessment criteria’ yield a dichotomous answer as to the presence or absence of high-risk prescribing while at population level, ‘prescribing indicators’ can be used to measure the percentage of vulnerable patients who are exposed. These distinctions are illustrated in <xref ref-type="table" rid="table2-2042098612444867">Box 1</xref> using the example of NSAID prescribing.</p>
<table-wrap id="table2-2042098612444867" position="float">
<label>Box 1.</label>
<caption>
<p>Illustration of the differences between implicit and explicit methods to assess medication use.</p>
</caption>
<graphic alternate-form-of="table2-2042098612444867" xlink:href="10.1177_2042098612444867-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Method of measurement</th>
<th/>
<th align="left">Measurement output</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3"><bold>Implicit, e.g. MAI [<xref ref-type="bibr" rid="bibr23-2042098612444867">Hanlon <italic>et al</italic>. 1992</xref>]</bold></td>
</tr>
<tr>
<td>Is the use of an NSAID appropriate in this patient with respect to contraindications, drug–drug interactions etc?</td>
<td><graphic id="img1-2042098612444867" position="anchor" xlink:href="10.1177_2042098612444867-img1.tif"/></td>
<td>Measure of appropriateness (e.g. on a three-point scale)</td>
</tr>
<tr>
<td colspan="3">Explicit</td>
</tr>
<tr>
<td colspan="3"><bold><italic>Medication Assessment Criteria, e.g. Beers criteria [<xref ref-type="bibr" rid="bibr14-2042098612444867">Fick et al. 2003</xref>], STOPP criteria [<xref ref-type="bibr" rid="bibr16-2042098612444867">Gallagher et al. 2008</xref>]</italic></bold></td>
</tr>
<tr>
<td>If a patient has a history of peptic ulcer, is he prescribed an NSAID without gastroprotection?</td>
<td><graphic id="img2-2042098612444867" position="anchor" xlink:href="10.1177_2042098612444867-img2.tif"/></td>
<td>High-risk prescribing present? Yes/No</td>
</tr>
<tr>
<td colspan="3"><bold><italic>Medication Safety Indicators, e.g. Scottish indicators [<xref ref-type="bibr" rid="bibr20-2042098612444867">Guthrie et al. 2011</xref>], PPRNet indicators [<xref ref-type="bibr" rid="bibr57-2042098612444867">Wessell et al. 2010</xref>]</italic></bold></td>
</tr>
<tr>
<td>Denominator: number of patients with a history of peptic ulcer (= ‘vulnerable’)/ Numerator: number of ‘vulnerable’ patients who are prescribed an NSAID without gastroprotection</td>
<td><graphic id="img3-2042098612444867" position="anchor" xlink:href="10.1177_2042098612444867-img3.tif"/></td>
<td>% of vulnerable patients with high-risk prescribing</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-2042098612444867">
<p>MAI, Medication Appropriateness Index; NSAID, nonsteroidal anti-inflammatory drug; PPRNet, Practice Partner Research Network; STOPP, Screening Tool of Older Persons potentially inappropriate Prescriptions.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section5-2042098612444867">
<title>Implicit measurement</title>
<p>The most prominent example of an implicit approach is the Medication Appropriateness Index (MAI), where each drug prescribed to a patient is assessed on a three-point scale (appropriate, marginally appropriate, inappropriate) in 10 domains: indication, effectiveness, dosage, directions, drug–drug interactions, drug-disease interactions, expense, practicality, duplication and duration [<xref ref-type="bibr" rid="bibr23-2042098612444867">Hanlon <italic>et al</italic>. 1992</xref>]. A merit of implicit methods is that they allow the assessment of a wide range of therapeutic issues and to judge the appropriateness of prescribing. However, they depend heavily on the knowledge, experience and skills of the reviewer and are time consuming [<xref ref-type="bibr" rid="bibr23-2042098612444867">Hanlon <italic>et al</italic>. 1992</xref>].</p>
</sec>
<sec id="section6-2042098612444867">
<title>Explicit measurement</title>
<p>Explicit approaches are narrower in scope and usually limited to identifying prescribing that is <italic>potentially</italic> inappropriate, but are more objective and less resource intensive. As a consequence, numerous explicit medication assessment tools have been developed over the last two decades [<xref ref-type="bibr" rid="bibr7-2042098612444867">Beers <italic>et al</italic>. 1991</xref>; <xref ref-type="bibr" rid="bibr38-2042098612444867">Naugler <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr14-2042098612444867">Fick <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr49-2042098612444867">Shrank <italic>et al</italic>. 2006</xref>, <xref ref-type="bibr" rid="bibr50-2042098612444867">2007</xref>; <xref ref-type="bibr" rid="bibr5-2042098612444867">Basger <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr16-2042098612444867">Gallagher <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr3-2042098612444867">Avery and Rodgers, 2010</xref>; <xref ref-type="bibr" rid="bibr57-2042098612444867">Wessell <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr20-2042098612444867">Guthrie <italic>et al</italic>. 2011</xref>]. Our focus here is on instruments which have been applied in larger-scale studies to measure the prevalence of high-risk or otherwise undesirable medication use in primary care.</p>
<sec id="section7-2042098612444867">
<title>Beers criteria</title>
<p>The most cited explicit assessment method is the ‘Beers criteria’, first published in 1991 [<xref ref-type="bibr" rid="bibr7-2042098612444867">Beers <italic>et al</italic>. 1991</xref>] and updated in 2003 [<xref ref-type="bibr" rid="bibr14-2042098612444867">Fick <italic>et al</italic>. 2003</xref>]. The instrument identifies drugs or dosing regimes that should be avoided in the elderly, either in general (e.g. long-acting benzodiazepines), or under specific circumstances (e.g. anticholinergic drugs in people with chronic constipation). The Beers criteria can be assessed relatively easily in routine healthcare data and have been widely applied as a result. Prevalence studies conducted in primary care have reported that between 15% and 30% patients aged 65 years and over were prescribed at least one potentially inappropriate medication listed in the set [<xref ref-type="bibr" rid="bibr58-2042098612444867">Willcox <italic>et al</italic>. 1994</xref>; <xref ref-type="bibr" rid="bibr60-2042098612444867">Zhan <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr4-2042098612444867">Ay <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr51-2042098612444867">Simon <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr56-2042098612444867">Van Der Hooft <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr12-2042098612444867">De Wilde <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr43-2042098612444867">Rajska-Neumann and Wieczorowska-Tobis, 2007</xref>; <xref ref-type="bibr" rid="bibr46-2042098612444867">Ryan <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr36-2042098612444867">Leikola <italic>et al</italic>. 2011</xref>]. The Beers criteria have been the gold standard for assessing medication use safety in the elderly for many years but have been criticized more recently because some of the drugs included have valid indications in older people and because of increasing evidence that most harm is caused by drugs which are not listed [<xref ref-type="bibr" rid="bibr20-2042098612444867">Guthrie <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section8-2042098612444867">
<title>STOPP criteria</title>
<p>The Screening Tool of Older Persons potentially inappropriate Prescriptions (STOPP) consists of 68 medication assessment criteria, which cover a broader spectrum of safety issues than the Beers set [<xref ref-type="bibr" rid="bibr16-2042098612444867">Gallagher <italic>et al</italic>. 2008</xref>]. STOPP not only targets drugs that should be avoided in the elderly but also considers high-risk drug–drug and drug–disease interactions and omissions of risk-mitigating agents. The clinical relevance of the STOPP criteria has been demonstrated in a recently published study, in which the instrument outperformed the updated Beers criteria in predicting the presence of pADEs that were sufficiently serious to contribute to hospital admission [<xref ref-type="bibr" rid="bibr22-2042098612444867">Hamilton <italic>et al</italic>. 2011</xref>]. High-risk prescribing according to STOPP was found to be common in a cross-sectional study of 1329 patients from three GP practices in Ireland, where approximately 1 in 5 (22%) patients aged 65 or older living at home had received one or more high-risk prescriptions in the previous 6 months [<xref ref-type="bibr" rid="bibr46-2042098612444867">Ryan <italic>et al</italic>. 2009</xref>]. Limitations of STOPP include that it exclusively focuses on the elderly, although vulnerability to drug-related harm, such as renal impairment or peptic ulcer, is not uncommon among younger patients. In addition, many items in STOPP rely on information that is rarely consistently recorded in electronic healthcare databases, which is a barrier to routine or large-scale application.</p>
</sec>
<sec id="section9-2042098612444867">
<title>PPRNet indicators</title>
<p>The relative lack of relevant tools to measure high-risk medication use from electronic medical records (EMRs) has led researchers from the Practice Partner Research Network (PPRNet) in the US to develop a new instrument for use in primary care [<xref ref-type="bibr" rid="bibr57-2042098612444867">Wessell <italic>et al</italic>. 2010</xref>]. The PPRNet tool consists of 30 medication safety indicators grouped into five categories (see below). The instrument was applied in a cross-sectional study including all patients aged over 18 years from 20 family practices in 17 US states (<italic>n</italic> = 52,246). Across all indicators, 61% of all patients met at least one indicator definition of being vulnerable because of their age, pre-existing disease, coprescription or being on treatment that requires laboratory monitoring [<xref ref-type="bibr" rid="bibr57-2042098612444867">Wessell <italic>et al</italic>. 2010</xref>]. ‘Potentially inappropriate prescribing’ and apparent shortcomings in ‘monitoring/preventing potential ADEs’ each affected approximately 25% of patients identified as vulnerable in each category. The rate of ‘potentially inappropriate dosing’ (16%) and ‘potential drug–disease interactions’ (14%) was lower and was lowest for ‘potential drug–drug interactions’ (2%).</p>
</sec>
<sec id="section10-2042098612444867">
<title>Scottish indicators of high-risk prescribing</title>
<p>Guided by similar motivations to the PPRNet researchers, we have recently completed a study to develop a set of medication safety indicators that can be operationalized within EMRs, using a modified RAND panel [<xref ref-type="bibr" rid="bibr15-2042098612444867">Fitch <italic>et al</italic>. 2003</xref>] of general practitioners and primary care pharmacists [<xref ref-type="bibr" rid="bibr13-2042098612444867">Dreischulte <italic>et al</italic>. 2012</xref>]. A subset of 15 indicators targeting high-risk prescribing of NSAIDs, warfarin, antipsychotic drugs, methotrexate and drugs that can aggravate heart failure was applied in a cross-sectional population database analysis of 1.76 million patients registered with 315 Scottish general practices in 2007 [<xref ref-type="bibr" rid="bibr20-2042098612444867">Guthrie <italic>et al</italic>. 2011</xref>]. There were 7.9% of registered patients who met at least one indicator definition of being vulnerable and 13.9% of these patients had received at least one high-risk prescription in the previous year.</p>
<p>Although the estimated prevalence depends on the indicator set used, it is clear that high-risk prescribing in primary care is common. In addition, the data presented here is likely to substantially underestimate its prevalence, since even instruments comprising a reasonably large number of indicators [<xref ref-type="bibr" rid="bibr14-2042098612444867">Fick <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr16-2042098612444867">Gallagher <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr57-2042098612444867">Wessell <italic>et al</italic>. 2010</xref>] cannot comprehensively cover the spectrum of medication safety. While it is important to note that only a fraction of patients affected by high-risk medication use will ultimately be injured, avoiding high-risk medication use where possible, and regularly reviewing such prescribing if it is judged to be essential, is a prerequisite to averting preventable harm. In our study of 315 general practices in Scotland, rates of high-risk prescribing varied approximately fourfold between practices after case mix adjustment [<xref ref-type="bibr" rid="bibr20-2042098612444867">Guthrie <italic>et al</italic>. 2011</xref>], suggesting considerable scope for reducing such prescribing.</p>
</sec>
</sec>
</sec>
<sec id="section11-2042098612444867">
<title>Quality improvement approaches</title>
<sec id="section12-2042098612444867">
<title>Root causes of preventable drug-related harm</title>
<p>There is relatively little research into the root causes of preventable drug-related harm. Nevertheless, a qualitative study conducted in 2004 provides useful insights into the weaknesses of medication use systems in UK primary care, which were associated with 18 common causes of preventable drug-related hospital admission [<xref ref-type="bibr" rid="bibr27-2042098612444867">Howard <italic>et al</italic>. 2007</xref>]. In all of these cases, preventable patient harm was the consequence of active failures at multiple stages of the medication use process, including prescribing, dispensing, administration, monitoring and help seeking by patients. High-risk prescribing was most commonly caused by knowledge gaps about patients’ medical and medication histories and insufficient pharmacotherapeutic knowledge of prescribers. Potential defence mechanisms against harm were frequently undermined by inadequacies in the design of computerized decision support systems (CDSSs), lack of access to relevant patient information by community pharmacists and communication problems between all stakeholders (GPs, hospital specialists, community pharmacists and patients). Workload pressures exacerbated these problems at all stages.</p>
</sec>
<sec id="section13-2042098612444867">
<title>Previously tested interventions</title>
<p>There is a large body of research examining changing professional practice to improve the quality of care, much of which has been systematically reviewed [<xref ref-type="bibr" rid="bibr33-2042098612444867">Jamtvedt <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr40-2042098612444867">O’Brien <italic>et al</italic>. 2007</xref>]. Strategies which have been successfully applied to improve medication use processes include the following:</p>
<list id="list1-2042098612444867" list-type="bullet">
<list-item><p>C<italic>DSSs, particularly when integrated into clinician’s workflow, and when alerts are system-activated rather than relying on user activation</italic> [<xref ref-type="bibr" rid="bibr17-2042098612444867">Garg <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr34-2042098612444867">Kawamoto <italic>et al</italic>. 2005</xref>]. A systematic review of CDSS studies focusing specifically on improving prescribing and monitoring [<xref ref-type="bibr" rid="bibr41-2042098612444867">Pearson <italic>et al</italic>. 2009</xref>] found that alerts were most consistently effective when they targeted the initiation of high-risk drugs rather than stopping existing treatments. For example, in a study of 107 Canadian primary care physicians, CDSS significantly reduced new high-risk prescriptions (NSAIDs, benzodiazepines, tricyclic antidepressants) but had no impact on stopping long-term use of hypnotics [<xref ref-type="bibr" rid="bibr53-2042098612444867">Tamblyn <italic>et al</italic>. 2003</xref>]. CDSS were also found to be effective in reminding clinicians to conduct laboratory tests for monitoring long-term treatments, such as warfarin [<xref ref-type="bibr" rid="bibr11-2042098612444867">Demakis <italic>et al</italic>. 2000</xref>].</p></list-item>
<list-item><p><italic>Feedback of performance data particularly when baseline performance is low and when feedback is more ‘intensive’ by targeting individuals, being verbal or prolonged, or when delivered by senior staff</italic> [<xref ref-type="bibr" rid="bibr33-2042098612444867">Jamtvedt <italic>et al</italic>. 2006</xref>]. Feedback, often in combination with educational outreach, has been shown to reduce high-risk NSAID prescribing [<xref ref-type="bibr" rid="bibr42-2042098612444867">Pit <italic>et al</italic>. 2007</xref>], excessive use of opioids and other regulated analgesics [<xref ref-type="bibr" rid="bibr1-2042098612444867">Anderson <italic>et al</italic>. 1996</xref>], and hypnotics in the elderly [<xref ref-type="bibr" rid="bibr52-2042098612444867">Smith <italic>et al</italic>. 1998</xref>].</p></list-item>
<list-item><p><italic>Pharmacist-led interventions targeted at patients and/or prescribers</italic> [<xref ref-type="bibr" rid="bibr45-2042098612444867">Royal <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr39-2042098612444867">Nkansah <italic>et al</italic>. 2010</xref>]. Multidisciplinary models involving pharmacists in primary care or outpatient settings have been shown to be successful in improving a wide range of endpoints relevant to medication safety, including reduction in therapeutic duplication and cessation of treatments no longer needed [<xref ref-type="bibr" rid="bibr39-2042098612444867">Nkansah <italic>et al</italic>. 2010</xref>], composites of high-risk prescribing and monitoring [<xref ref-type="bibr" rid="bibr3-2042098612444867">Avery and Rodgers, 2010</xref>], reductions in medications implicated in falls [<xref ref-type="bibr" rid="bibr59-2042098612444867">Zermansky <italic>et al</italic>. 2006</xref>] and overall improvement in medication appropriateness [<xref ref-type="bibr" rid="bibr24-2042098612444867">Hanlon <italic>et al</italic>. 1996</xref>].</p></list-item>
</list>
<p>Overall, it is important to note that the effectiveness of these three types of intervention varies between studies, and few have been shown to improve patient as opposed to prescribing outcomes [<xref ref-type="bibr" rid="bibr45-2042098612444867">Royal <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr26-2042098612444867">Holland <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr39-2042098612444867">Nkansah <italic>et al</italic>. 2010</xref>]. This may in part be attributable to the fact that many trials to date have used outcome measures that are insufficiently sensitive to improvements in medication use (e.g. quality of life or all-cause rather than drug-related hospitalization)[<xref ref-type="bibr" rid="bibr45-2042098612444867">Royal <italic>et al</italic>. 2006</xref>]. However, in view of the complexity of the medication use system in primary care [<xref ref-type="bibr" rid="bibr27-2042098612444867">Howard <italic>et al</italic>. 2007</xref>], it may also reflect the limitations of approaches that target specific aspects of a single process, such as prescribing.</p>
</sec>
<sec id="section14-2042098612444867">
<title>Proposal for an integrated system to improve medication safety</title>
<p>The high disease burden associated with high-risk prescribing, the large numbers of patients affected, and the fact that shortcomings in the primary care infrastructure are an important underlying cause, call for a more systematic approach to improving medication safety. The increasing use of EMRs in primary care offer new opportunities to integrate complementary defence mechanisms against preventable ADEs from high-risk prescribing or monitoring deficiencies. EMRs can be exploited: (1) to implement CDSS alerts that prompt prescribers to explicitly consider patient vulnerability at the time of decision making; (2) to systematically identify patients who have received high-risk prescriptions or are due monitoring tests for targeted review and follow up; and (3) to provide timely and continuous performance feedback to monitor prescribing patterns and identify those in need of improvement. Although these three approaches have strong face validity, a number of challenges and uncertainties remain with respect to their specific design and implementation.</p>
</sec>
</sec>
<sec id="section15-2042098612444867">
<title>Challenges for implementation and future research</title>
<sec id="section16-2042098612444867">
<title>Decision support</title>
<p>A commonly reported problem in existing CDSSs is that highly important alerts are often ignored, because practitioners are desensitized by multiple alerts of minimal clinical relevance (alert fatigue). A US study from 2009 found that physicians ignored &gt;90% of alerts with little association with the severity of the alert [<xref ref-type="bibr" rid="bibr32-2042098612444867">Isaac <italic>et al</italic>. 2009</xref>]. The authors conclude that the ‘systems and the computers that are supposed to make physicians’ lives better are actually torturing them’ [<xref ref-type="bibr" rid="bibr32-2042098612444867">Isaac <italic>et al</italic>. 2009</xref>]. The ability to customize alerts to the preferences of users may therefore be crucial in this respect, but requires careful selection of prompts that should always be considered because of potentially serious consequences [<xref ref-type="bibr" rid="bibr48-2042098612444867">Sheikh <italic>et al</italic>. 2011</xref>]. A further problem is that alerts often only trigger when a drug is newly prescribed, meaning that prescribers will not explicitly be alerted to situations where continued prescribing becomes high risk due to changes in clinical circumstances [<xref ref-type="bibr" rid="bibr20-2042098612444867">Guthrie <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section17-2042098612444867">
<title>Systematic follow up of patients at risk of adverse events</title>
<p>Even with optimal implementation, patients may still slip through the system of alerts that are triggered at the time of decision making. EMRs can be used to facilitate systematic identification, regular review and monitoring of patients to identify where such treatments are necessary or have been issued by mistake. For example, dual antiplatelet treatment with aspirin and clopidogrel is strongly indicated after myocardial infarction or stent implementation but at least doubles the risk of bleeding compared with aspirin alone [<xref ref-type="bibr" rid="bibr10-2042098612444867">Delaney <italic>et al</italic>. 2007</xref>]. Regularly searching EMRs for patients where treatment duration is longer than recommended will ensure that patients do not inadvertently continue a medication that is no longer indicated. In addition, a systematic approach to identifying patients for review may also allow distributing the associated workload across the multidisciplinary team. ‘For example, although high-risk prescribing is currently not a UK Quality and Outcomes Framework (QOF) topic, QOF financial incentives have stimulated practices to identify patients who are not treated according to evidence-based practice standards in order to improve their care, and this has significantly been achieved by the greater involvement of practice nurses in delivering systematic chronic disease management’ [<xref ref-type="bibr" rid="bibr21-2042098612444867">Grant <italic>et al</italic>. 2009</xref>]. Pharmacists might play a similarly important role in reviewing high-risk prescribing.</p>
<p>Collaboration in medication management, and in particular a greater role for pharmacists in primary care, have long been advocated [<xref ref-type="bibr" rid="bibr54-2042098612444867">The Scottish Government, 2010</xref>; <xref ref-type="bibr" rid="bibr8-2042098612444867">Bond <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr44-2042098612444867">Roth <italic>et al</italic>. 2009</xref>]. However, shared access to relevant patient information and adequate funding are prerequisites for more effective collaboration [<xref ref-type="bibr" rid="bibr27-2042098612444867">Howard <italic>et al</italic>. 2007</xref>]. In addition, better integration of services provided by doctors and pharmacists is likely to also rely on overcoming the more tacit interprofessional barriers [<xref ref-type="bibr" rid="bibr30-2042098612444867">Hughes and McCann, 2003</xref>; <xref ref-type="bibr" rid="bibr27-2042098612444867">Howard <italic>et al</italic>. 2007</xref>] and on providing pharmacists with the necessary skills to function in a professional role that is still new to many [<xref ref-type="bibr" rid="bibr27-2042098612444867">Howard <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr35-2042098612444867">Krskaj and Avery, 2007</xref>; <xref ref-type="bibr" rid="bibr47-2042098612444867">Salter <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section18-2042098612444867">
<title>Performance feedback</title>
<p>Decision support alerts can be complemented by routine feedback of prescribing safety data in order to monitor the performance of the medication use system as a whole. For example, indicator scores (percentage of vulnerable patients affected by high-risk prescribing) can be compared with internal or external benchmarks in order to identify variations in prescribing that need further investigation. However, most reported audit and feedback interventions are one off rather than sustained, and performance feedback is often limited to a small number of indicators [<xref ref-type="bibr" rid="bibr42-2042098612444867">Pit <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr3-2042098612444867">Avery and Rodgers, 2010</xref>], which are only likely to address a fraction of the wide spectrum of high-risk medication use. Although EMRs make it feasible to assess medication use against a wider range of assessment criteria, more research will be required to test different ways of data feedback that do not overwhelm practitioners [<xref ref-type="bibr" rid="bibr19-2042098612444867">Guthrie <italic>et al</italic>. 2005</xref>]. Composite performance scores can make data presentation more efficient, but are often not sufficiently specific to guide the selection of actionable targets for improvement [<xref ref-type="bibr" rid="bibr31-2042098612444867">Hysong <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr18-2042098612444867">Guthrie, 2008</xref>].</p>
<p>In view of the plethora of potentially unsafe medication use practices it is clear that decision support alerts, criteria used to target patients for review and indicators used in performance feedback will require prioritization by clinical relevance. However, this is often undermined by a lack of primary evidence about the degree of harm. For example, the risks of many drug–drug interactions, such as coprescribing of NSAIDs with ACE inhibitors and diuretics (the ‘triple whammy’ [<xref ref-type="bibr" rid="bibr37-2042098612444867">Loboz and Shenfield, 2005</xref>]), are not well quantified, and the evidence to support many monitoring recommendations is very limited. The growth of large, linkable electronic databases should allow more systematic study of the risks of prescribing in primary care in the future.</p>
</sec>
</sec>
<sec id="section19-2042098612444867">
<title>Conclusions</title>
<p>Despite major differences in measurement instruments, high-risk prescribing in primary care has been shown to be common, consistent with a lack of focus on medication safety in the past. Aging populations and the associated increase in the prevalence of multimorbidity and polypharmacy is likely to further exacerbate the problem of preventable drug-related morbidity. It is time for concerted efforts to improve the safety of medication use in primary care, which is likely to require multifaceted approaches across the entire spectrum of prescribing and monitoring processes.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors, but during the writing of this paper, TD was funded by Scottish Government Chief Scientist Office Applied Research Programme (grant number 07/02). The funder had no role in writing the paper.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors have no conflicts of interest to declare.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>J.F.</given-names></name>
<name><surname>Mcewan</surname><given-names>K.L.</given-names></name>
<name><surname>Hrudey</surname><given-names>W.P.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Effectiveness of notification and group education in modifying prescribing of regulated analgesics</article-title>. <source>CMAJ Can Med Assoc J</source> <volume>154</volume>: <fpage>31</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr2-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aronson</surname><given-names>J.K.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Medication errors: what they are, how they happen, and how to avoid them</article-title>. <source>QJM</source> <volume>102</volume>: <fpage>513</fpage>–<lpage>521</lpage>.</citation>
</ref>
<ref id="bibr3-2042098612444867">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Avery</surname><given-names>A.</given-names></name>
<name><surname>Rodgers</surname><given-names>S.</given-names></name>
</person-group> (<year>2010</year>) <source>The Pincer Trial (‘A Cluster Randomised Trial to Determine the Effectiveness, Costs/Benefits and Acceptability of a Pharmacist-Led, IT-Based Intervention Compared with Simple Feedback in Reducing Rates of Clinically Important Instances of Potentially Hazardous Prescribing and Medicines Management in General Practice’): Final Report</source>. <publisher-loc>Nottingham</publisher-loc>: <publisher-name>University of Nottingham</publisher-name>.</citation>
</ref>
<ref id="bibr4-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ay</surname><given-names>P.</given-names></name>
<name><surname>Akici</surname><given-names>A.</given-names></name>
<name><surname>Harmanc</surname><given-names>H.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Drug utilization and potentially inappropriate drug use in elderly residents of a community in Istanbul, Turkey</article-title>. <source>Int J Clin Pharmacol Ther</source> <volume>43</volume>: <fpage>195</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr5-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Basger</surname><given-names>B.J.</given-names></name>
<name><surname>Chen</surname><given-names>T.F.</given-names></name>
<name><surname>Moles</surname><given-names>R.J.</given-names></name>
<name><surname>Basger</surname><given-names>B.J.</given-names></name>
<name><surname>Chen</surname><given-names>T.F.</given-names></name>
<name><surname>Moles</surname><given-names>R.J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Inappropriate medication use and prescribing indicators in elderly Australians: development of a prescribing indicators tool</article-title>. <source>Drugs Aging</source> <volume>25</volume>: <fpage>777</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr6-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bates</surname><given-names>D.W.</given-names></name>
<name><surname>Cullen</surname><given-names>D.J.</given-names></name>
<name><surname>Laird</surname><given-names>N.</given-names></name>
<name><surname>Petersen</surname><given-names>L.A.</given-names></name>
<name><surname>Small</surname><given-names>S.D.</given-names></name>
<name><surname>Servi</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>1995</year>) <article-title>Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group</article-title>. <source>JAMA</source> <volume>274</volume>: <fpage>29</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr7-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beers</surname><given-names>M.H.</given-names></name>
<name><surname>Ouslander</surname><given-names>J.G.</given-names></name>
<name><surname>Rollingher</surname><given-names>J.</given-names></name>
<name><surname>Reuben</surname><given-names>D.B.</given-names></name>
<name><surname>Beck</surname><given-names>J.C.</given-names></name>
</person-group> (<year>1991</year>) <article-title>Explicit criteria for determining inappropriate medication use in nursing home residents</article-title>. <source>Arch Intern Med</source> <volume>151</volume>: <fpage>1825</fpage>–<lpage>1832</lpage>.</citation>
</ref>
<ref id="bibr8-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bond</surname><given-names>C.</given-names></name>
<name><surname>Matheson</surname><given-names>C.</given-names></name>
<name><surname>Williams</surname><given-names>S.</given-names></name>
<name><surname>Williams</surname><given-names>P.</given-names></name>
<name><surname>Donnan</surname><given-names>P.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Repeat prescribing: a role for community pharmacists in controlling and monitoring repeat prescriptions</article-title>. <source>Br J Gen Practice</source> <volume>50</volume>: <fpage>271</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr9-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cribb</surname><given-names>A.</given-names></name>
<name><surname>Barber</surname><given-names>N.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Prescribers, patients and policy: the limits of technique</article-title>. <source>Health Care Anal</source> <volume>5</volume>: <fpage>292</fpage>–<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr10-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delaney</surname><given-names>J.A.</given-names></name>
<name><surname>Opatrny</surname><given-names>L.</given-names></name>
<name><surname>Brophy</surname><given-names>J.M.</given-names></name>
<name><surname>Suissa</surname><given-names>S.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding</article-title>. <source>CMAJ Can Med Assoc J</source> <volume>177</volume>: <fpage>347</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr11-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Demakis</surname><given-names>J.</given-names></name>
<name><surname>Beauchamp</surname><given-names>C.</given-names></name>
<name><surname>Cull</surname><given-names>W.</given-names></name>
<name><surname>Denwood</surname><given-names>R.</given-names></name>
<name><surname>Eisen</surname><given-names>S.</given-names></name>
<name><surname>Lofgren</surname><given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Improving residents’ compliance with standards of ambulatory care. Results from the VA Cooperative Study on Computerized Reminders</article-title>. <source>JAMA</source> <volume>284</volume>: <fpage>1411</fpage>–<lpage>1416</lpage>.</citation>
</ref>
<ref id="bibr12-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Wilde</surname><given-names>S.</given-names></name>
<name><surname>Carey</surname><given-names>I.M.</given-names></name>
<name><surname>Harris</surname><given-names>T.</given-names></name>
<name><surname>Richards</surname><given-names>N.</given-names></name>
<name><surname>Victor</surname><given-names>C.</given-names></name>
<name><surname>Hilton</surname><given-names>S.R.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Trends in potentially inappropriate prescribing amongst older UK primary care patients</article-title>. <source>Pharmacoepidemiol Drug Safety</source> <volume>16</volume>: <fpage>658</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr13-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dreischulte</surname><given-names>T.</given-names></name>
<name><surname>Grant</surname><given-names>A.</given-names></name>
<name><surname>McCowan</surname><given-names>C.</given-names></name>
<name><surname>McAnaw</surname><given-names>J.</given-names></name>
<name><surname>Guthrie</surname><given-names>B.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Quality and safety of medication use in primary care: Consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement</article-title>. <source>BMC Clinical Pharmacology</source> <volume>12</volume>:<fpage>5</fpage>.</citation>
</ref>
<ref id="bibr14-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fick</surname><given-names>D.M.</given-names></name>
<name><surname>Cooper</surname><given-names>J.W.</given-names></name>
<name><surname>Wade</surname><given-names>W.E.</given-names></name>
<name><surname>Waller</surname><given-names>J.L.</given-names></name>
<name><surname>Maclean</surname><given-names>J.R.</given-names></name>
<name><surname>Beers</surname><given-names>M.H.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts</article-title>. <source>Arch Intern Med</source> <volume>163</volume>: <fpage>2716</fpage>–<lpage>2724</lpage>.</citation>
</ref>
<ref id="bibr15-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fitch</surname><given-names>K.</given-names></name>
<name><surname>Bernstein</surname><given-names>S.</given-names></name>
<name><surname>Aguilar</surname><given-names>M.</given-names></name>
<name><surname>Burnand</surname><given-names>B.</given-names></name>
<name><surname>Lacalle</surname><given-names>J.</given-names></name>
<name><surname>Lazaro</surname><given-names>P.</given-names></name>
</person-group> (<year>2003</year>) <source>The RAND/UCLA Appropriateness Method User’s Manual</source>. <comment>Rand Corporation</comment></citation>
</ref>
<ref id="bibr16-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gallagher</surname><given-names>P.</given-names></name>
<name><surname>Ryan</surname><given-names>C.</given-names></name>
<name><surname>Byrne</surname><given-names>S.</given-names></name>
<name><surname>Kennedy</surname><given-names>J.</given-names></name>
<name><surname>O’Mahony</surname><given-names>D.</given-names></name>
</person-group> (<year>2008</year>) <article-title>STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment). Consensus validation</article-title>. <source>Int J Clin Pharmacol Therapeut</source> <volume>46</volume>: <fpage>72</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr17-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garg</surname><given-names>A.</given-names></name>
<name><surname>Adhikari</surname><given-names>N.</given-names></name>
<name><surname>McDonald</surname><given-names>H.</given-names></name>
<name><surname>Rosas-Arellano</surname><given-names>M.</given-names></name>
<name><surname>Devereaux</surname><given-names>P.</given-names></name>
<name><surname>Beyene</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Effects of computerized clinical decision support systems on practitioner performance and patient outcomes. A systematic review</article-title>. <source>JAMA</source> <volume>293</volume>: <fpage>1223</fpage>–<lpage>1238</lpage>.</citation>
</ref>
<ref id="bibr18-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guthrie</surname><given-names>B.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Measuring the quality of healthcare systems using composites</article-title>. <source>BMJ</source> <volume>337</volume>: <fpage>a639</fpage>.</citation>
</ref>
<ref id="bibr19-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guthrie</surname><given-names>B.</given-names></name>
<name><surname>Love</surname><given-names>T.</given-names></name>
<name><surname>Fahey</surname><given-names>T.</given-names></name>
<name><surname>Morris</surname><given-names>A.</given-names></name>
<name><surname>Sullivan</surname><given-names>F.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Control, compare and communicate: designing control charts to summarise efficiently data from multiple quality indicators</article-title>. <source>Qual Saf Health Care</source> <volume>14</volume>: <fpage>450</fpage>–<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr20-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guthrie</surname><given-names>B.</given-names></name>
<name><surname>McCowan</surname><given-names>C.</given-names></name>
<name><surname>Davey</surname><given-names>P.</given-names></name>
<name><surname>Simpson</surname><given-names>C.R.</given-names></name>
<name><surname>Dreischulte</surname><given-names>T.</given-names></name>
<name><surname>Barnett</surname><given-names>K.</given-names></name>
</person-group> (<year>2011</year>) <article-title>High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice</article-title>. <source>BMJ</source> <volume>342</volume>. DOI: 10.1136/bmj.d3514<pub-id pub-id-type="doi">10.1136/bmj.d3514</pub-id>.</citation>
</ref>
<ref id="bibr21-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grant</surname><given-names>S.</given-names></name>
<name><surname>Huby</surname><given-names>G.</given-names></name>
<name><surname>Watkins</surname><given-names>F.</given-names></name>
<name><surname>Checkland</surname><given-names>K.</given-names></name>
<name><surname>McDonald</surname><given-names>R.</given-names></name>
<name><surname>Davies</surname><given-names>H.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>The impact of pay-for-performance on professional boundaries in UK general practice: an ethnographic study</article-title>. <source>Sociol Health Illness</source> <volume>31</volume>: <fpage>229</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr22-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hamilton</surname><given-names>H.</given-names></name>
<name><surname>Gallagher</surname><given-names>P.</given-names></name>
<name><surname>Ryan</surname><given-names>C.</given-names></name>
<name><surname>Byrne</surname><given-names>S.</given-names></name>
<name><surname>O’Mahony</surname><given-names>D.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Potentially inappropriate medications defined by STOPP Criteria and the risk of adverse drug events in older hospitalized patients</article-title>. <source>Arch Intern Med</source> <volume>171</volume>: <fpage>1013</fpage>–<lpage>1019</lpage>.</citation>
</ref>
<ref id="bibr23-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanlon</surname><given-names>J.T.</given-names></name>
<name><surname>Schmader</surname><given-names>K.E.</given-names></name>
<name><surname>Samsa</surname><given-names>G.P.</given-names></name>
<name><surname>Weinberger</surname><given-names>M.</given-names></name>
<name><surname>Uttech</surname><given-names>K.M.</given-names></name>
<name><surname>Lewis</surname><given-names>I.K.</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>A method for assessing drug therapy appropriateness</article-title>. <source>J Clin Epidemiol</source> <volume>45</volume>: <fpage>1045</fpage>–<lpage>1051</lpage>.</citation>
</ref>
<ref id="bibr24-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanlon</surname><given-names>J.T.</given-names></name>
<name><surname>Weinberger</surname><given-names>M.</given-names></name>
<name><surname>Samsa</surname><given-names>G.P.</given-names></name>
<name><surname>Schmader</surname><given-names>K.E.</given-names></name>
<name><surname>Uttech</surname><given-names>K.M.</given-names></name>
<name><surname>Lewis</surname><given-names>I.K.</given-names></name>
<etal/>
</person-group>. (<year>1996</year>) <article-title>A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy</article-title>. <source>Am J Med</source> <volume>100</volume>: <fpage>428</fpage>–<lpage>437</lpage>.</citation>
</ref>
<ref id="bibr25-2042098612444867">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hepler</surname><given-names>C.D.</given-names></name>
<name><surname>Segal</surname><given-names>R.</given-names></name>
</person-group> (<year>2003</year>) <source>Preventing Medication Errors and Improving Drug Therapy Outcomes</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>.</citation>
</ref>
<ref id="bibr26-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holland</surname><given-names>R.</given-names></name>
<name><surname>Desborough</surname><given-names>J.</given-names></name>
<name><surname>Goodyer</surname><given-names>L.</given-names></name>
<name><surname>Hall</surname><given-names>S.</given-names></name>
<name><surname>Wright</surname><given-names>D.</given-names></name>
<name><surname>Loke</surname><given-names>Y.K.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis</article-title>. <source>Br J Clin Pharmacol</source> <volume>65</volume>: <fpage>303</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr27-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howard</surname><given-names>R.</given-names></name>
<name><surname>Avery</surname><given-names>A.</given-names></name>
<name><surname>Bissell</surname><given-names>P.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Causes of preventable drug-related hospital admissions: a qualitative study</article-title>. <source>Qual Saf Health Care</source> <volume>17</volume>: <fpage>109</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr28-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howard</surname><given-names>R.</given-names></name>
<name><surname>Avery</surname><given-names>A.J.</given-names></name>
<name><surname>Howard</surname><given-names>P.D.</given-names></name>
<name><surname>Partridge</surname><given-names>M.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study</article-title>. <source>Qual Saf Health Care</source> <volume>12</volume>: <fpage>280</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr29-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howard</surname><given-names>R.</given-names></name>
<name><surname>Avery</surname><given-names>A.J.</given-names></name>
<name><surname>Slavenburg</surname><given-names>S.</given-names></name>
<name><surname>Royal</surname><given-names>S.</given-names></name>
<name><surname>Pipe</surname><given-names>G.</given-names></name>
<name><surname>Lucassen</surname><given-names>P.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Which drugs cause preventable admissions to hospital? A systematic review</article-title>. <source>Br J Clin Pharmacol</source> <volume>63</volume>: <fpage>136</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr30-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughes</surname><given-names>C.M.</given-names></name>
<name><surname>McCann</surname><given-names>S.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Perceived interprofessional barriers between community pharmacists and general practitioners: a qualitative assessment</article-title>. <source>Br J Gen Practice</source> <volume>53</volume>: <fpage>600</fpage>–<lpage>606</lpage>.</citation>
</ref>
<ref id="bibr31-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hysong</surname><given-names>S.J.</given-names></name>
<name><surname>Best</surname><given-names>R.G.</given-names></name>
<name><surname>Pugh</surname><given-names>J.A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Audit and feedback and clinical practice guideline adherence: making feedback actionable</article-title>. <source>Implement Sci</source>. DOI: 10.1186/1748-5908-1181–1189<pub-id pub-id-type="doi">10.1186/1748-5908-1181–1189</pub-id>.</citation>
</ref>
<ref id="bibr32-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isaac</surname><given-names>T.</given-names></name>
<name><surname>Weissman</surname><given-names>J.S.</given-names></name>
<name><surname>Davis</surname><given-names>R.B.</given-names></name>
<name><surname>Massagli</surname><given-names>M.</given-names></name>
<name><surname>Cyrulik</surname><given-names>A.</given-names></name>
<name><surname>Sands</surname><given-names>D.Z.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Overrides of medication alerts in ambulatory care</article-title>. <source>Arch Intern Med</source> <volume>169</volume>: <fpage>305</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr33-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jamtvedt</surname><given-names>G.</given-names></name>
<name><surname>Young</surname><given-names>J.M.</given-names></name>
<name><surname>Kristoffersen</surname><given-names>D.T.</given-names></name>
<name><surname>O’Brien</surname><given-names>M.A.</given-names></name>
<name><surname>Oxman</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Audit and feedback: effects on professional practice and health care outcomes (review)</article-title>. <source>Cochrane Database Syst Rev</source> <volume>2</volume>: <fpage>CD000259</fpage>.</citation>
</ref>
<ref id="bibr34-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kawamoto</surname><given-names>K.</given-names></name>
<name><surname>Houlihan</surname><given-names>C.</given-names></name>
<name><surname>Balas</surname><given-names>E.</given-names></name>
<name><surname>Lobach</surname><given-names>D.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success</article-title>. <source>BMJ</source> <volume>330</volume>: <fpage>765</fpage>.</citation>
</ref>
<ref id="bibr35-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krska</surname><given-names>J.</given-names></name>
<name><surname>Avery</surname><given-names>T.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Evaluation of medication reviews conducted by community pharmacists: a quantitative analysis of documented issues and recommendations</article-title>. <source>Br J Clin Pharmacol</source> <volume>65</volume>: <fpage>386</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr36-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leikola</surname><given-names>S.</given-names></name>
<name><surname>Dimitrow</surname><given-names>M.</given-names></name>
<name><surname>Lyles</surname><given-names>A.</given-names></name>
<name><surname>Pitkala</surname><given-names>K.</given-names></name>
<name><surname>Airaksinen</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Potentially inappropriate medication use among Finnish non-institutionalized people aged &gt;/=65 years: a register-based, cross-sectional, national study</article-title>. <source>Drugs Aging</source> <volume>28</volume>: <fpage>227</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr37-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loboz</surname><given-names>K.K.</given-names></name>
<name><surname>Shenfield</surname><given-names>G.M.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Drug combinations and impaired renal function – the triple whammy</article-title>. <source>Br J Clin Pharmacol</source> <volume>59</volume>: <fpage>239</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr38-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naugler</surname><given-names>C.T.</given-names></name>
<name><surname>Brymer</surname><given-names>C.</given-names></name>
<name><surname>Stolee</surname><given-names>P.</given-names></name>
<name><surname>Arcese</surname><given-names>Z.A.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Development and validation of an improving prescribing in the elderly tool</article-title>. <source>Can J Clin Pharmacol</source> <volume>7</volume>: <fpage>103</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr39-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nkansah</surname><given-names>N.</given-names></name>
<name><surname>Mostovetsky</surname><given-names>O.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Chheng</surname><given-names>T.</given-names></name>
<name><surname>Beney</surname><given-names>J.</given-names></name>
<name><surname>Bond</surname><given-names>C.M.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Effect of outpatient pharmacists’ non-dispensing roles on patient outcomes and prescribing patterns</article-title>. <source>Cochrane Database Syst Rev</source> <volume>7</volume>: <fpage>CD000336</fpage>.</citation>
</ref>
<ref id="bibr40-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>M.A.</given-names></name>
<name><surname>Rogers</surname><given-names>S.</given-names></name>
<name><surname>Jamtvedt</surname><given-names>G.</given-names></name>
<name><surname>Oxman</surname><given-names>A.D.</given-names></name>
<name><surname>Odgaard-Jensen</surname><given-names>J.</given-names></name>
<name><surname>Kristoffersen</surname><given-names>D.T.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Educational outreach visits: effects on professional practice and health care outcomes</article-title>. <source>Cochrane Database Syst Rev</source> <volume>4</volume>: <fpage>CD000409</fpage>.</citation>
</ref>
<ref id="bibr41-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pearson</surname><given-names>S.-A.</given-names></name>
<name><surname>Moxey</surname><given-names>A.</given-names></name>
<name><surname>Robertson</surname><given-names>J.</given-names></name>
<name><surname>Hains</surname><given-names>I.</given-names></name>
<name><surname>Williamson</surname><given-names>M.</given-names></name>
<name><surname>Reeve</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Do computerised clinical decision support systems for prescribing change practice? A systematic review of the literature (1990-2007)</article-title>. <source>BMC Health Services Res</source> <volume>9</volume>: <fpage>154</fpage>.</citation>
</ref>
<ref id="bibr42-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pit</surname><given-names>S.W.</given-names></name>
<name><surname>Byles</surname><given-names>J.E.</given-names></name>
<name><surname>Henry</surname><given-names>D.A.</given-names></name>
<name><surname>Holt</surname><given-names>L.</given-names></name>
<name><surname>Hansen</surname><given-names>V.</given-names></name>
<name><surname>Bowman</surname><given-names>D.A.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>A quality use of medicines program for general practitioners and older people: a cluster randomised controlled trial</article-title>. <source>Med J Australia</source> <volume>187</volume>: <fpage>23</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr43-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajska-Neumann</surname><given-names>A.</given-names></name>
<name><surname>Wieczorowska-Tobis</surname><given-names>K.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Polypharmacy and potential inappropriateness of pharmaco-logical treatment among community-dwelling elderly patients</article-title>. <source>Arch Gerontol Geriatr</source> <volume>44</volume>(<supplement>Suppl. 1</supplement>): <fpage>303</fpage>–<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr44-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roth</surname><given-names>M.T.</given-names></name>
<name><surname>Weinberger</surname><given-names>M.</given-names></name>
<name><surname>Campbell</surname><given-names>W.H.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Measuring the quality of medication use in older adults</article-title>. <source>JAGS</source> <volume>57</volume>: <fpage>1096</fpage>–<lpage>1102</lpage>.</citation>
</ref>
<ref id="bibr45-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Royal</surname><given-names>S.</given-names></name>
<name><surname>Smeaton</surname><given-names>L.</given-names></name>
<name><surname>Avery</surname><given-names>A.J.</given-names></name>
<name><surname>Hurwitz</surname><given-names>B.</given-names></name>
<name><surname>Sheikh</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis</article-title>. <source>Qual Saf Health Care</source> <volume>15</volume>: <fpage>23</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr46-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ryan</surname><given-names>C.</given-names></name>
<name><surname>O’Mahony</surname><given-names>D.</given-names></name>
<name><surname>Kennedy</surname><given-names>J.</given-names></name>
<name><surname>Weedle</surname><given-names>P.</given-names></name>
<name><surname>Byrne</surname><given-names>S.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Potentially inappropriate prescribing in an Irish elderly population in primary care</article-title>. <source>Br J Clin Pharmacol</source> <volume>68</volume>: <fpage>936</fpage>–<lpage>947</lpage>.</citation>
</ref>
<ref id="bibr47-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salter</surname><given-names>C.</given-names></name>
<name><surname>Holland</surname><given-names>R.</given-names></name>
<name><surname>Harvey</surname><given-names>R.</given-names></name>
<name><surname>Henwood</surname><given-names>K.</given-names></name>
</person-group> (<year>2007</year>) <article-title>“I haven’t even phoned my doctor yet.” The advice giving role of the pharmacist during consultations for medication review with patients aged 80 or more: qualitative discourse analysis</article-title>. <source>BMJ</source> <volume>334</volume>: <fpage>1101</fpage>–<lpage>1104</lpage>.</citation>
</ref>
<ref id="bibr48-2042098612444867">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Sheikh</surname><given-names>A.</given-names></name>
<name><surname>Mclean</surname><given-names>S.</given-names></name>
<name><surname>Cresswell</surname><given-names>K.</given-names></name>
<name><surname>Pagliari</surname><given-names>C.</given-names></name>
<name><surname>Pappas</surname><given-names>Y.</given-names></name>
<name><surname>Car</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>The impact of ehealth on the quality and safety of healthcare. An updated systematic overview &amp; synthesis of the literature</article-title>. <comment>Final Report for the NHS Connecting for Health Evaluation Programme (NHS CFHEP 001)</comment>. <publisher-loc>London</publisher-loc>: <publisher-name>Department of Health</publisher-name>.</citation>
</ref>
<ref id="bibr49-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shrank</surname><given-names>W.H.</given-names></name>
<name><surname>Asch</surname><given-names>S.M.</given-names></name>
<name><surname>Adams</surname><given-names>J.</given-names></name>
<name><surname>Setodji</surname><given-names>C.</given-names></name>
<name><surname>Kerr</surname><given-names>E.A.</given-names></name>
<name><surname>Keesey</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>The quality of pharmacologic care for adults in the United States</article-title>. <source>Med Care</source> <volume>44</volume>: <fpage>936</fpage>–<lpage>945</lpage>.</citation>
</ref>
<ref id="bibr50-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shrank</surname><given-names>W.H.</given-names></name>
<name><surname>Polinski</surname><given-names>J.M.</given-names></name>
<name><surname>Avorn</surname><given-names>J.</given-names></name>
<name><surname>Shrank</surname><given-names>W.H.</given-names></name>
<name><surname>Polinski</surname><given-names>J.M.</given-names></name>
<name><surname>Avorn</surname><given-names>J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Quality indicators for medication use in vulnerable elders</article-title>. <source>J Am Geriatr Soc</source> <volume>55</volume>(<supplement>Suppl. 2</supplement>): <fpage>S373</fpage>–<lpage>S382</lpage>.</citation>
</ref>
<ref id="bibr51-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simon</surname><given-names>S.R.</given-names></name>
<name><surname>Chan</surname><given-names>K.A.</given-names></name>
<name><surname>Soumerai</surname><given-names>S.B.</given-names></name>
<name><surname>Wagner</surname><given-names>A.K.</given-names></name>
<name><surname>Andrade</surname><given-names>S.E.</given-names></name>
<name><surname>Feldstein</surname><given-names>A.C.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Potentially inappropriate medication use by elderly persons in U.S. health maintenance organizations, 2000–2001</article-title>. <source>J Am Geriatr Soc</source> <volume>53</volume>: <fpage>227</fpage>–<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr52-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>D.H.</given-names></name>
<name><surname>Christensen</surname><given-names>D.B.</given-names></name>
<name><surname>Stergachis</surname><given-names>A.</given-names></name>
<name><surname>Holmes</surname><given-names>G.</given-names></name>
</person-group> (<year>1998</year>) <article-title>A randomized controlled trial of a drug use review intervention for sedative hypnotic medications</article-title>. <source>Med Care</source> <volume>36</volume>: <fpage>1013</fpage>–<lpage>1021</lpage>.</citation>
</ref>
<ref id="bibr53-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tamblyn</surname><given-names>R.</given-names></name>
<name><surname>Huang</surname><given-names>A.</given-names></name>
<name><surname>Perreault</surname><given-names>R.</given-names></name>
<name><surname>Jacques</surname><given-names>A.</given-names></name>
<name><surname>Roy</surname><given-names>D.</given-names></name>
<name><surname>Hanley</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care</article-title>. <source>Can Med Assoc J</source> <volume>169</volume>: <fpage>549</fpage>–<lpage>556</lpage>.</citation>
</ref>
<ref id="bibr54-2042098612444867">
<citation citation-type="web">
<collab>The Scottish Government</collab> (<year>2010</year>) <article-title>The NHS chronic medication service at your local pharmacy - a new service for people with a long-term condition</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://wwwcommunitypharmacyscotnhsuk/core_services/cmshtml">http://wwwcommunitypharmacyscotnhsuk/core_services/cmshtml</ext-link></comment> (<access-date>accessed 26 February 2011</access-date>).</citation>
</ref>
<ref id="bibr55-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomsen</surname><given-names>L.A.</given-names></name>
<name><surname>Winterstein</surname><given-names>A.G.</given-names></name>
<name><surname>Søndergaard</surname><given-names>B.</given-names></name>
<name><surname>Haugbølle</surname><given-names>L.S.</given-names></name>
<name><surname>Melander</surname><given-names>A.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care</article-title>. <source>Ann Pharmacother</source> <volume>41</volume>: <fpage>1411</fpage>–<lpage>1426</lpage>.</citation>
</ref>
<ref id="bibr56-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Der Hooft</surname><given-names>C.S.</given-names></name>
<name><surname>Jong</surname><given-names>G.W.</given-names></name>
<name><surname>Dieleman</surname><given-names>J.P.</given-names></name>
<name><surname>Verhamme</surname><given-names>K.M.</given-names></name>
<name><surname>Van Der Cammen</surname><given-names>T.J.</given-names></name>
<name><surname>Stricker</surname><given-names>B.H.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria - a population-based cohort study</article-title>. <source>Br J Clin Pharmacol</source> <volume>60</volume>: <fpage>137</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr57-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wessell</surname><given-names>A.M.</given-names></name>
<name><surname>Litvin</surname><given-names>C.</given-names></name>
<name><surname>Jenkins</surname><given-names>R.G.</given-names></name>
<name><surname>Nietert</surname><given-names>P.J.</given-names></name>
<name><surname>Nemeth</surname><given-names>L.S.</given-names></name>
<name><surname>Ornstein</surname><given-names>S.M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Medication prescribing and monitoring errors in primary care: a report from the practice partner research network</article-title>. <source>Qual Saf Health Care</source> <volume>19</volume>: <fpage>e21</fpage>.</citation>
</ref>
<ref id="bibr58-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willcox</surname><given-names>S.M.</given-names></name>
<name><surname>Himmelstein</surname><given-names>D.U.</given-names></name>
<name><surname>Woolhandler</surname><given-names>S.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Inappropriate drug prescribing for the community-dwelling elderly</article-title>. <source>JAMA</source> <volume>272</volume>: <fpage>292</fpage>–<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr59-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zermansky</surname><given-names>A.G.</given-names></name>
<name><surname>Alldred</surname><given-names>D.P.</given-names></name>
<name><surname>Petty</surname><given-names>D.R.</given-names></name>
<name><surname>Raynor</surname><given-names>D.K.</given-names></name>
<name><surname>Freemantle</surname><given-names>N.</given-names></name>
<name><surname>Eastaugh</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Clinical medication review by a pharmacist of elderly people living in care homes - randomised controlled trial</article-title>. <source>Age Ageing</source> <volume>35</volume>: <fpage>586</fpage>–<lpage>591</lpage>.</citation>
</ref>
<ref id="bibr60-2042098612444867">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhan</surname><given-names>C.</given-names></name>
<name><surname>Sangl</surname><given-names>J.</given-names></name>
<name><surname>Bierman</surname><given-names>A.S.</given-names></name>
<name><surname>Miller</surname><given-names>M.R.</given-names></name>
<name><surname>Friedman</surname><given-names>B.</given-names></name>
<name><surname>Wickizer</surname><given-names>S.W.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 medical expenditure panel survey</article-title>. <source>JAMA</source> <volume>286</volume>: <fpage>2823</fpage>–<lpage>2829</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>